Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

Scientists from illuma and Nestlé were among the first to realize the significance of HMOs in human milk more than 30 years ago. Their pioneering research led to over 75 published papers; over 100 patents relating to HMOs. The brand has carried out more than 55 HMO-related studies, including more than 30 clinical trials. Children worldwide can now benefit from multifunctional HMOs thanks to the application of these study findings, which have led to the provision of a wide range of HMO-containing food products for children, from preterm infants to preschoolers, in more than 100 countries.

Each illuma formula is crafted out with tremendous investment, continuous innovations and rigorous trials and checks. With the approval of two HMOs in China, illuma is eager to develop a next generation HMOs formula for Chinese babies. —a precise and harmonious combination featuring the 2-approved-HMOs, various innate HMOs from base powder, α-lactalbumin, and MFGM, to support infant immunity and offer enhanced protection for newborns in China. This well-expected illuma HMO formula will soon be available in China, which offers infants the best nutritional solutions available worldwide.

View original content:https://www.prnewswire.co.uk/news-releases/illuma-global-pioneer-in-hmo-research-launches-traceability-journey-in-switzerland-unveiling-next-generation-hmo-innovations-302275343.html